JCR Pharmaceuticals Co., Ltd. (JCRRF) Stock Price & Analysis
JCR Pharmaceuticals Co., Ltd. (JCRRF) — price $3.73 (0.00%), as of the Nov 19, 2026 trading session; market cap $456M.
Educational signal · not a buy or sell recommendation · How to read this
JCR Pharmaceuticals Co., Ltd. · JCRRF
It addresses therapeutic areas including growth hormone deficiency, rare genetic disorders, and acute graft-versus-host disease, while actively developing treatments for renal anemia.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.73 | |
| Change on the day | 0.00% | |
| 52-week range | $3.14 – $4.75 | |
| Market capitalisation | $456M | — |
| Price / earnings (trailing) | 80.95 | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for JCR Pharmaceuticals Co. (JCRRF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is JCR Pharmaceuticals Co. (JCRRF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. JCR Pharmaceuticals Co., Ltd. (JCRRF) is the company analyzed here. It employs 985 people and is led by Toru Ashida. In Q2 FY2027 it reported revenue of ¥10.39B and net income of -¥1.98B. The market values it at $456M.
What do the latest results show for JCR Pharmaceuticals Co. (JCRRF)?
Short answer · as of
The most recent reported quarter, Q2 FY2027, carried revenue of ¥10.39B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2027 | ¥10.39B | -¥1.98B | -¥15.91 (diluted) |
| Q1 FY2027 | ¥9.63B | -¥1.89B | -¥15.52 (diluted) |
| Q4 FY2026 | ¥10.03B | ¥438M | ¥3.58 (diluted) |
| Q3 FY2026 | ¥9.00B | ¥34M | ¥0.28 (diluted) |
What are the financial strengths and risks for JCR Pharmaceuticals Co. (JCRRF)?
Short answer · as of
The distress and quality screens read Altman Z 1.13 · Piotroski F 1. Trailing ratios: ROE -7.7% · ROA -3.0% · current ratio 0.93 · earnings yield -5.5% · free-cash-flow yield -9.3%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.13 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-7.7%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held JCRRF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported JCRRF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about JCR Pharmaceuticals Co. (JCRRF)?
- JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
- Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America
- JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy
What Investors Ask About JCR Pharmaceuticals Co. (JCRRF)
These answers are editorial: 1 of these 8 answers is drawn from the JCRRF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is JCRRF a good stock to buy?
Stock Expert AI does not rate JCRRF buy, sell or hold. JCR Pharmaceuticals Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the JCRRF stock price today?
The last price recorded for JCR Pharmaceuticals Co., Ltd. (JCRRF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for JCRRF?
JCRRF faces several key risks inherent to the pharmaceutical industry and its OTC market listing. Potential risks include regulatory delays or outright failure in securing approvals for its pipeline products, such as the renal anemia treatments, which could significantly impact future revenue streams.
What are the key factors to evaluate for JCRRF?
Evaluate JCRRF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. This segment represents a high-growth, innovative frontier in healthcare. Not financial advice.
How frequently does JCRRF data refresh on this page?
JCRRF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven JCRRF's recent stock price performance?
JCR Pharmaceuticals Co., Ltd. (JCRRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established portfolio of specialized pharmaceutical products for rare and critical conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider JCRRF overvalued or undervalued right now?
The trailing P/E of JCR Pharmaceuticals Co., Ltd. (JCRRF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research JCRRF before investing?
Before investing in JCR Pharmaceuticals Co., Ltd. (JCRRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com